References
- Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001;15:1949-1958. https://doi.org/10.1046/j.1365-2036.2001.01109.x
- Wotherspoon AC, Doglioni C, Diss TC, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993;342:575-577. https://doi.org/10.1016/0140-6736(93)91409-F
- Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085-1095. https://doi.org/10.1056/NEJMoa1708423
- Korean Helicobacter pylori Study Group. Diagnosis and treatment of Helicobacter pylori infection in Korea. Korean J Gastroenterol 1998;32:275-289.
- Kim N, Kim JJ, Choe YH, et al. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2009;54:269-278. https://doi.org/10.4166/kjg.2009.54.5.269
- Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. Korean J Gastroenterol 2013;62:3-26. https://doi.org/10.4166/kjg.2013.62.1.3
- Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 2013;132:1272-1276. https://doi.org/10.1002/ijc.27965
- Ford AC, Forman D, Hunt R, Yuan Y, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2015;(7):CD005583.
- Lee JH, Choi KD, Jung HY, et al. Seroprevalence of Helicobacter pylori in Korea: a multicenter, nationwide study conducted in 2015 and 2016. Helicobacter 2018;23:e12463. https://doi.org/10.1111/hel.12463
- Shin WG, Lee SW, Baik GH, et al. Eradication rates of Helicobacter pylori in Korea over the past 10 years and correlation of the amount of antibiotics use: nationwide survey. Helicobacter 2016;21:266-278. https://doi.org/10.1111/hel.12279
- Kim BJ, Kim HS, Song HJ, et al. Online registry for nationwide database of current trend of Helicobacter pylori eradication in Korea: interim analysis. J Korean Med Sci 2016;31:1246-1253. https://doi.org/10.3346/jkms.2016.31.8.1246
- Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-1153. https://doi.org/10.1136/gut.2009.192757
- Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 2017;112:212-239. https://doi.org/10.1038/ajg.2016.563
- Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017;66:6-30. https://doi.org/10.1136/gutjnl-2016-312288
- Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-1600. https://doi.org/10.1111/j.1440-1746.2009.05982.x
- Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000;14:715-718. https://doi.org/10.1046/j.1365-2036.2000.00766.x
- Rinaldi V, Zullo A, Pugliano F, Valente C, Diana F, Attili AF. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 1997;11:929-933. https://doi.org/10.1046/j.1365-2036.1997.00228.x
- Maconi G, Parente F, Russo A, Vago L, Imbesi V, Bianchi Porro G. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 2001;96:359-366.
- De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006;144:94-100. https://doi.org/10.7326/0003-4819-144-2-200601170-00006
- Jung YS, Park CH, Park JH, Nam E, Lee HL. Efficacy of Helicobacter pylori eradication therapies in Korea: a systematic review and network meta-analysis. Helicobacter 2017;22:e12389. https://doi.org/10.1111/hel.12389
- Kim YS, Kim SJ, Yoon JH, et al. Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. Aliment Pharmacol Ther 2011;34:1098-1105. https://doi.org/10.1111/j.1365-2036.2011.04843.x
- Choi HS, Chun HJ, Park SH, et al. Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol 2012;18:2377-2382. https://doi.org/10.3748/wjg.v18.i19.2377
- Chung JW, Jung YK, Kim YJ, et al. Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial. J Gastroenterol Hepatol 2012;27:1675-1680. https://doi.org/10.1111/j.1440-1746.2012.07249.x
- Lam SK, Talley NJ. Report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998;13:1-12. https://doi.org/10.1111/j.1440-1746.1998.tb00537.x
- Gatta L, Scarpignato C, Fiorini G, et al. Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains. Aliment Pharmacol Ther 2018;47:1261-1269. https://doi.org/10.1111/apt.14597
- Gong EJ, Ahn JY. Antimicrobial resistance of Helicobacter pylori isolates in Korea. Korean J Helicobacter Up Gastrointest Res 2018;18:82-88. https://doi.org/10.7704/kjhugr.2018.18.2.82
- Hwang JJ, Lee DH, Yoon H, Shin CM, Park YS, Kim N. Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication. World J Gastroenterol 2015;21:10234-10241. https://doi.org/10.3748/wjg.v21.i35.10234
- Hwang JJ, Lee DH, Lee AR, et al. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. World J Gastroenterol 2015;21:5032-5038. https://doi.org/10.3748/wjg.v21.i16.5032
- Lim JH, Lee DH, Choi C, et al. Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study. Helicobacter 2013;18:180-186. https://doi.org/10.1111/hel.12034
- Kim SY, Lee SW, Hyun JJ, et al. Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy. J Clin Gastroenterol 2013;47:21-24. https://doi.org/10.1097/MCG.0b013e3182548ad4
- Chung JW, Han JP, Kim KO, et al. Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: a multicenter, prospective study. Dig Liver Dis 2016;48:888-892. https://doi.org/10.1016/j.dld.2016.05.005
- Lee HJ, Kim JI, Lee JS, et al. Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies. World J Gastroenterol 2015;21:351-359. https://doi.org/10.3748/wjg.v21.i1.351
- Lee JY, Ahn JY, Choi IJ. Historical perspective of Helicobacter pylori treatment in Korea. Korean J Helicobacter Up Gastrointest Res 2015;15:211-221. https://doi.org/10.7704/kjhugr.2015.15.4.211
- Gisbert JP, Calvet X, O'Connor A, Megraud F, O'Morain CA. Sequential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010;44:313-325.
- Kang BK, Park SM, Kim BW. New therapeutic strategies against Helicobacter pylori. Korean J Gastroenterol 2014;63:146-150. https://doi.org/10.4166/kjg.2014.63.3.146
- Park SM, Kim JS, Kim BW, Ji JS, Choi H. Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection. J Gastroenterol Hepatol 2017;32:589-594. https://doi.org/10.1111/jgh.13510
- Kim SY, Lee SW, Choe JW, et al. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. Helicobacter 2017;22:e12441. https://doi.org/10.1111/hel.12441
- Bae HJ, Kim JS, Kim BW, Nam YJ. Concomitant or sequential therapy as the first-line therapy for eradication of Helicobacter pylori infection in Korea: a systematic review and meta-analysis. Korean J Gastroenterol 2018;71:31-37. https://doi.org/10.4166/kjg.2018.71.1.31
- Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587. https://doi.org/10.1136/bmj.f4587
- He L, Deng T, Luo H. Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 2015;54:703-710. https://doi.org/10.2169/internalmedicine.54.3442
- Apostolopoulos P, Koumoutsos I, Ekmektzoglou K, et al. Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study. Scand J Gastroenterol 2016;51:145-151. https://doi.org/10.3109/00365521.2015.1079646
- Jang HJ, Choi MH, Kim YS, et al. Effectiveness of triple therapy and quadruple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2005;46:368-372.
- Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343-357. https://doi.org/10.1111/j.1365-2036.2007.03386.x
- Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013;(12):CD008337.
- Lee ST, Lee DH, Lim JH, et al. Efficacy of 7-day and 14-day bismuth-containing quadruple therapy and 7-day and 14-day moxifloxacin-based triple therapy as second-line eradication for Helicobacter pylori infection. Gut Liver 2015;9:478-485. https://doi.org/10.5009/gnl14020
- Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010;15:38-45. https://doi.org/10.1111/j.1523-5378.2009.00735.x
- Boyanova L, Mitov I. Geographic map and evolution of primary Helicobacter pylori resistance to antibacterial agents. Expert Rev Anti Infect Ther 2010;8:59-70. https://doi.org/10.1586/eri.09.113
- Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34-42. https://doi.org/10.1136/gutjnl-2012-302254
- Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011;16:139-145. https://doi.org/10.1111/j.1523-5378.2011.00828.x
- Hsu PI, Wu DC, Wu JY, Graham DY. Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days? Helicobacter 2011;16:146-152. https://doi.org/10.1111/j.1523-5378.2011.00829.x
- Oh DH, Lee DH, Kang KK, et al. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. J Gastroenterol Hepatol 2014;29:1171-1176. https://doi.org/10.1111/jgh.12518
- Heo J, Jeon SW, Jung JT, et al. Concomitant and hybrid therapy for Helicobacter pylori infection: a randomized clinical trial. J Gastroenterol Hepatol 2015;30:1361-1366. https://doi.org/10.1111/jgh.12983
- Garcia N, Calvet X, Gene E, Campo R, Brullet E. Limited usefulness of a seven-day twice-a-day quadruple therapy. Eur J Gastroenterol Hepatol 2000;12:1315-1318. https://doi.org/10.1097/00042737-200012120-00008
- Zhang W, Chen Q, Liang X, et al. Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy. Gut 2015;64:1715-1720. https://doi.org/10.1136/gutjnl-2015-309900
- Chen Q, Zhang W, Fu Q, et al. Rescue therapy for Helicobacter pylori eradication: a randomized non-inferiority trial of amoxicillin or tetracycline in bismuth quadruple therapy. Am J Gastroenterol 2016;111:1736-1742. https://doi.org/10.1038/ajg.2016.443
- Choe JW, Jung SW, Kim SY, et al. Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea. Helicobacter 2018;23:e12466. https://doi.org/10.1111/hel.12466
- Scott DR, Munson KB, Marcus EA, Lambrecht NW, Sachs G. The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase. Aliment Pharmacol Ther 2015;42:1315-1326. https://doi.org/10.1111/apt.13414
- Jenkins H, Sakurai Y, Nishimura A, et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium- competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther 2015;41:636-648. https://doi.org/10.1111/apt.13121
- Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther 2015;42:719-730. https://doi.org/10.1111/apt.13325
- Sachs G, Scott DR, Wen Y. Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep 2011;13:540-546. https://doi.org/10.1007/s11894-011-0226-4
- Murakami K, Sakurai Y, Shiino M, Funao N, Nishimura A, Asaka M. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Gut 2016;65:1439-1446. https://doi.org/10.1136/gutjnl-2015-311304
- Maruyama M, Tanaka N, Kubota D, et al. Vonoprazan-based regimen is more useful than PPI-based one as a first-line Helicobacter pylori eradication: a randomized controlled trial. Can J Gastroenterol Hepatol 2017;2017:4385161.
- Jung YS, Kim EH, Park CH. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. Aliment Pharmacol Ther 2017;46:106-114. https://doi.org/10.1111/apt.14130
- Lee JY, Kim N. Future trends of Helicobacter pylori eradication therapy in Korea. Korean J Gastroenterol 2014;63:158-170. https://doi.org/10.4166/kjg.2014.63.3.158
- Lee HJ, Kim JI, Cheung DY, et al. Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance. J Infect Dis 2013;208:1123-1130. https://doi.org/10.1093/infdis/jit287
- Chen H, Dang Y, Zhou X, Liu B, Liu S, Zhang G. Tailored therapy versus empiric chosen treatment for Helicobacter pylori eradication: a meta-analysis. Medicine (Baltimore) 2016;95:e2750. https://doi.org/10.1097/MD.0000000000002750
- Lopez-Gongora S, Puig I, Calvet X, et al. Systematic review and meta-analysis: susceptibility-guided versus empirical antibiotic treatment for Helicobacter pylori infection. J Antimicrob Chemother 2015;70:2447-2455. https://doi.org/10.1093/jac/dkv155
Cited by
- Best Helicobacter pylori Eradication Strategy in the Era of Antibiotic Resistance vol.9, pp.8, 2018, https://doi.org/10.3390/antibiotics9080436